This could be explained by the fact that rapamycin-mediated mTOR inhibition and autophagy activation, while reducing the proliferative and metabolic activity of tumor cells, may promote the enrichment of dormant cancer cells that remain viable but exhibit low proliferative and metabolic activity [15,53]. The gene discussed is MTOR; the disease is cancer.